LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

NCT03361306 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Elotuzumab

Sponsor

Wake Forest University Health Sciences

Collaborators

Bristol-Myers Squibb
Atrium Health Levine Cancer Institute